Immunon (Nasdaq: IMMN) shares rose over 200% in pre-market trading today to $3.37 after the U.S. clinical-stage company published data from the Phase 2 OVATION 2 trial of its interleukin-12 (IL-12) immunotherapy drug IMNN-001 in patients with advanced ovarian cancer.
Results showed that all patients treated with IMNN-001 experienced a median improvement in overall survival (OS) of 11 months. In patients who received three or more doses of IMNN-001 (91% of the intent-to-treat population), median OS increased to 15.7 months.
The study also revealed that:
This article is available to registered users only. To continue reading, please sign up for free. Your free trial will give you access to one week of exclusive features, interviews, roundups and commentary from some of the sharpest minds in the pharma and biotechnology sector. If you’re already a registered user, please log in. If your trial has expired, you can sign up here.
Log in to your account
Try before you buy
free
7-day trial access
Try our free trial. We bring you all the news that matters in the world of pharma and biotech. Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences journalists. Receive The Pharma Letter’s daily breaking news bulletins, free forever.
Become a subscriber
£820
Or £77 per month
Subscribe now Get unlimited access to leading pharma and biotech news, commentary and analysis. Latest updates on clinical trials, conferences, M&A, licensing, funding, regulatory, patent and legal, executive appointments, commercial strategies and financial results. A daily roundup of major pharma and biotech events. An in-depth monthly briefing on executive appointments and M&A news. Choose from our cost-effective annual package or flexible monthly subscriptions. Pharma Letter is a highly useful and valuable life sciences service that brings together daily updates on performance, talent and products. It’s a vital piece of information to keep you informed.
Chairman of Sanofi-Aventis UK
Sign up to receive email updates
Get daily news from leaders in biotech and pharmaceuticals
